€24.50
+0.40 (+1.66%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MEDCL.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 2 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 PreventionNCT05305560results2024-12-10COVID-19 ProphylaxisRandomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Ivermectin Tablets, Matching placebo tablets | COVID-19 | 400 | 2022-09-15actual | 2024-12-31 |
| Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19NCT04632706results2021-12-27Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax])Randomized · Double-masked · OtherStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Ivermectin, Placebo | Covid19 | 24 | 2021-03-09actual | 2021-12-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19